Forbes: Mylan’s EpiPen Price ‘Cut’ an Outdated Drug Industry PR Move

Forbes: Mylan’s EpiPen Price ‘Cut’ an Outdated Drug Industry PR Move

“Mylan is simply the latest drug maker trying to re-frame a pricing problem into a coverage problem,” said Mark Merritt, president of the Pharmaceutical Care Management Association.